Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
MSCL.TOthis companySatellos Bioscience Inc.	CA$10.12	-4.58×	4.17×	0×	-3.93×	-93.6%	0.0%	0.0%	0.0%	-91.3%	-97.1%	-20.8%	0×	0.36×	0×	7.77×	0.0%	1	16.77	1	C-
CRDL.TOCardiol Therapeutics Inc.	CA$1.40	-3.36×	6.37×	0×	-2.71×	-83.2%	0.0%	0.0%	0.0%	-189.2%	-190.6%	-21.0%	0.01×	0.62×	0×	4.16×	0.0%	2	5.98	2	C
CYBN.NECybin Inc.	CA$12.78	-1.59×	1.01×	0×	-0.54×	-62.3%	0.0%	0.0%	0.0%	-63.2%	-60.9%	-57.1%	0×	1.11×	-48.88×	9.52×	0.0%	3	8.63	2	C
HBP.TOHelix BioPharma Corp.	CA$0.90	-34.09×	8.05×	0×	-32.25×	-104.3%	0.0%	0.0%	0.0%	-23.6%	-19.7%	-3.8%	0.29×	-0.92×	-20.22×	0.19×	0.0%	1	-7.69	1	D+
MDNA.TOMedicenna Therapeutics Corp.	CA$0.45	-2.91×	21.45×	0×	-1.99×	-91.3%	0.0%	0.0%	0.0%	-741.7%	-725.4%	0.0%	0.05×	0.26×	0×	1.52×	0.0%	0	-30.04	2	C
RX.VBioSyent Inc.	CA$17.95	15.91×	3.46×	3.33×	10.19×	15.5%	74.6%	26.3%	20.9%	21.7%	20.0%	6.7%	0.02×	-1.6×	229.23×	5.51×	1.6%	5	10.66	4	A
Peer median	—	-2.91×	6.37×	0×	-1.99×	-83.2%	0.0%	0.0%	0.0%	-63.2%	-60.9%	-3.8%	0.02×	0.26×	0×	4.16×	0.0%	2	5.98	2	—